02 Dec Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO- 112 + STING agonist published in Journal for ImmunoTherapy of Cancer
Results of a pre-clinical in vivo study of intra-tumoral co-injections of BO-112 and the DXMAA STING agonist conducted by Cima demonstrated synergistic efficacy with the ability to eradicate distant, uninjected tumor lesions. The combination of BO-112 and DMXAA was chosen because of its excellent efficacy,...